Blackpool CCG medicines optimisation

Blackpool CCG medicines optimisation

Medicines play an important part in promoting well-being, preventing ill health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines management can be defined in several ways:

  • The clinical, cost-effective, safe and secure handling of medicines
  • A system of processes and behaviours that determines how medicines are used by the NHS and patients
  • Enabling people to make the best possible use of medicines
  • Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s medicines management team on 01253 951306 or email blackpool.medicinesoptimisation@nhs.net


 

Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

NameSizeHits
28 Day Prescribing 0.3 MB150
Camouflaging Products 0.2 MB14
Cannabis based medicinal products for pain POSITION STATEMENT 0.3 MB137
Clinical Need Low Priority Medicines - General 0.3 MB266
Clinical Need Soluble Analgesics 0.5 MB172
Clinical Need Thickeners Position Statement 0.3 MB117
Commercial sponsorship and joint working with the pharmaceutical industry 0.6 MB104
Denosumab Position Statement 0.3 MB100
E-Cigarettes-Position-Statement-v2.0-FINAL-FOR-LMMG-WEBSITE[1] 0.2 MB149
Edoxaban Position Statement 0.2 MB119
Emollients and Sunscreens 0.2 MB193
Free of Charge (FOC) Medicines schemes 0.3 MB107
Generic Biosimilar Medicines Position Statement 0.2 MB107
Generic Prescribing Guidelines 0.3 MB190
Glucose Monitoring Devices 0.5 MB157
Gluten Free Foodstuffs 0.2 MB121
Health Professionals e-cigarettes briefing 0.2 MB94
Holiday Medication 0.2 MB168
Liothyronine 0.2 MB98
Ophthalmology Macular Pathways 1.1 MB106
Oral Nutritional Supplements (ONS) in care and nursing homes 0.2 MB166
Out of Area Prescribing 0.2 MB78
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus 0.3 MB140
Position Statement OPIOID PRESCRIBING max dose Final Version 1.1 0.1 MB6
Position Statement Sip Feeds 0.4 MB115
Prescribing Nutritional Supplements Post Bariatric Surgery 0.3 MB117
Prescribing of multivitamins and phenylalanine-free amino acid substitutes for adults and children with phenylketonuria (PKU) 0.7 MB99
Prescribing Vitamins And Minerals 0.3 MB98
Prophylactic supply of catheters post pelvic organ prolapse 0.2 MB86
Stoma Care Products - deodorants and air fresheners 0.4 MB125
Trans Anal Irrigation Devices 0.2 MB101
Vitamin D Position Statement 0.2 MB26
Zero Risk Schemes 0.3 MB90

Prescribing guidance

NameSizeHits
Axial-Spondyloarthritis-pathway-Version 37 KB81
Blood glucose meters and test strips Type 2 Diabetes V2.3 0.5 MB233
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB113
Chronic Non-cancer Pain Guidelines 0.7 MB92
Colomycin prescribing information sheet Non CF indications. 0.2 MB79
Constipation-Pathway-Version 0.7 MB168
COPD guideline 0.6 MB127
Diabetes - Glucagon Like Peptide Contract 0.2 MB120
Diabetes - Home Monitoring of Blood Glucose Levels Guideline 0.2 MB121
DIABETES Algorithm-for-antihyperglycaemic-therapy-in-adults-with-type-II-v1.5[1] 0.5 MB109
Diabetes-self-management-contract 0.5 MB155
Edoxaban Prescribing Tip 68 KB156
Erectile-Dysfunction-Guideline-Version 1.0 MB129
Flash Glucose Monitoring policy - L&SC 0.2 MB78
Gastroenterology-Biologics-Pathway-Version 0.4 MB130
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB100
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB184
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB55
Headache Management Guideline for Adults 0.7 MB68
Hydroxychloroquine-prescriber-information-sheet-v.1.0-FOR-WEBSITE 0.5 MB89
Insulin Toujeo Information Sheet and Good Practice Guide 0.3 MB53
Interim Gender Dysphoria protocol 0.6 MB88
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB135
LSCMMG OTC Items that Should not be Routinely Prescribed in Primary Care... 0.2 MB4
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB116
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB189
Neuropathic Pain Guidance (Version 1.2) 0.9 MB116
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB107
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB93
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB127
Primary Care Good Prescribing Guide 0.6 MB174
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB103
Psoriasis LMMG Biologic and High Cost Drug Commissioning Pathway v-1.6[1] 0.4 MB149
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB128
RA-High-Cost-Drugs-Pathway-v 0.2 MB120
Restless Legs Syndrome guidelines 0.3 MB75
Rheumatoid Arthritis Pathway Guideline 0.1 MB3
SIP Feeds 0.1 MB137
Trans male prescribing information sheet 0.2 MB25
Trans-female-gender-dysphoria-prescribing-information-sheet-version-1.1[1] 0.2 MB11
Wound care formulary 8.2 MB179

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document: www.lancsmmg.nhs.uk/pgds

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Clenil Modulite (Beclometasone) – Started July 2019
  • Fencino (Fentanyl) – Started October 2018
  • Firmagon (Degarelix) – Started September 2016
  • Januvia (Sitagliptin)  – Started September 2018
  • Lixiana (Edoxaban) – Started October 2018
  • Longtec (Oxycodone SR) – Started July 2019
  • Sereflo (Fluticasone / Salmeterol) – Started June 2019
  • Seretide (Fluticasone / Salmeterol) – Started January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started October 2018
  • Xarelto (Rivaroxaban) – Started July 2019
  • Zoladex (Goserelin) – Started January 2019

Last updated on 18 December 2019 at 11:11 by communications and engagement manager